Trial Profile

A clinical study of SG 293.

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 26 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SG 293 (Primary)
Indications Autoimmune disorders; Cancer; Non-Hodgkin's lymphoma
Focus First in man; Therapeutic Use

Most Recent Events

12 May 2026 According to Sana Biotechnology media release, Sana is preparing to begin clinical testing as early as mid-2027, contingent upon the early clinical profile of SG293.
25 Mar 2026 New trial record
04 Mar 2026 According to Sana Biotechnology media release, intends to explore SG293 in both B-cell cancers and B-cell mediated autoimmune diseases and expects to generate first-in-human data as early as this year.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com